The Capital BlueCross formulary is a reference list of prescription drugs that contains a wide range of generic and brand drugs that have been approved by the U.S. Food and Drug Administration (FDA). The formulary is updated on a quarterly basis or when new generic or brand-name medications become available and as discontinued drugs are removed from the marketplace.
Additional Recall Information:
The FDA announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac). The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity. As a result of this immediate market withdrawal request, ranitidine products will not be available for new or existing prescriptions or OTC use in the U.S.
Several new drugs have come to market and are now included in our formulary.
Pharmacy Management Program Update
(PAR) = Prior Authorization Required
(EPA) = Enhanced Prior Authorization Required
(QLL) = Quantity Level Limits Apply — Quantity Level Limit (QLL) Program
(BP) = Brand Preferred
(BNP) = Brand Non-Preferred
(NC) = Not Covered
(NF) = Non-Formulary
UPPERCASE names = Brand
lowercase names = Generic